{"entity":{"id":"nct00777153","kind":"trial","name":"Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma","aka":["REGAL"],"tldr":"A phase 3 trial of Cediranib in Glioma & glioblastoma, run by AstraZeneca, completed.","summary":"Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma is a phase 3 interventional study registered as NCT00777153 by AstraZeneca, with 423 participants recorded, started 2008-10 and reaching its primary completion in 2010-04. Interventions recorded: Cediranib, Cediranib, Lomustine Chemotherapy, Placebo Cediranib. Conditions recorded: Recurrent Glioblastoma.\n\nLinked to the drug Cediranib because the registry names it among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00777153","url":"https://clinicaltrials.gov/study/NCT00777153"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cediranib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00777153","phase":"3","setting":"A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone","sponsor":"AstraZeneca","started":"2008-10","yearReported":2012,"enrolled":423,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression Free Survival (PFS)","primary":true,"unit":"days","arms":[{"name":"Cediranib 30mg","n":131,"value":92,"note":"IQR 80 to 128; Figures from the ClinicalTrials.gov results section (first posted 2012-12-21), not from a publication"},{"name":"Cediranib 20mg+ Lomustine 110mg","n":129,"value":125,"note":"IQR 83 to 201"},{"name":"Lomustine 110mg","n":65,"value":82,"note":"IQR 42 to 168"}],"source":"https://clinicaltrials.gov/study/NCT00777153?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"Cediranib 30mg","n":131,"value":8,"note":"IQR 4.1 to 14.5; Figures from the ClinicalTrials.gov results section (first posted 2012-12-21), not from a publication"},{"name":"Cediranib 20mg + Lomustine 110mg","n":129,"value":9.4,"note":"IQR 6.2 to 14.5"},{"name":"Lomustine 110mg","n":65,"value":9.8,"note":"IQR 4.9 to NA"}],"source":"https://clinicaltrials.gov/study/NCT00777153?tab=results"}]},"route":"/trials/nct00777153/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"cediranib","kind":"drug","name":"Cediranib","route":"/drugs/cediranib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}